Cargando…
Galectins and Ovarian Cancer
Ovarian cancer is known for its aggressive pathological features, including the capacity to undergo epithelial to mesenchymal transition, promoting angiogenesis, metastatic potential, chemoresistance, inhibiting apoptosis, immunosuppression and promoting stem-like features. Galectins, a family of gl...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352943/ https://www.ncbi.nlm.nih.gov/pubmed/32486344 http://dx.doi.org/10.3390/cancers12061421 |
_version_ | 1783557758905221120 |
---|---|
author | Shimada, Chisa Xu, Rui Al-Alem, Linah Stasenko, Marina Spriggs, David R. Rueda, Bo R. |
author_facet | Shimada, Chisa Xu, Rui Al-Alem, Linah Stasenko, Marina Spriggs, David R. Rueda, Bo R. |
author_sort | Shimada, Chisa |
collection | PubMed |
description | Ovarian cancer is known for its aggressive pathological features, including the capacity to undergo epithelial to mesenchymal transition, promoting angiogenesis, metastatic potential, chemoresistance, inhibiting apoptosis, immunosuppression and promoting stem-like features. Galectins, a family of glycan-binding proteins defined by a conserved carbohydrate recognition domain, can modulate many of these processes, enabling them to contribute to the pathology of ovarian cancer. Our goal herein was to review specific galectin members identified in the context of ovarian cancer, with emphasis on their association with clinical and pathological features, implied functions, diagnostic or prognostic potential and strategies being developed to disrupt their negative actions. |
format | Online Article Text |
id | pubmed-7352943 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-73529432020-07-15 Galectins and Ovarian Cancer Shimada, Chisa Xu, Rui Al-Alem, Linah Stasenko, Marina Spriggs, David R. Rueda, Bo R. Cancers (Basel) Review Ovarian cancer is known for its aggressive pathological features, including the capacity to undergo epithelial to mesenchymal transition, promoting angiogenesis, metastatic potential, chemoresistance, inhibiting apoptosis, immunosuppression and promoting stem-like features. Galectins, a family of glycan-binding proteins defined by a conserved carbohydrate recognition domain, can modulate many of these processes, enabling them to contribute to the pathology of ovarian cancer. Our goal herein was to review specific galectin members identified in the context of ovarian cancer, with emphasis on their association with clinical and pathological features, implied functions, diagnostic or prognostic potential and strategies being developed to disrupt their negative actions. MDPI 2020-05-31 /pmc/articles/PMC7352943/ /pubmed/32486344 http://dx.doi.org/10.3390/cancers12061421 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Shimada, Chisa Xu, Rui Al-Alem, Linah Stasenko, Marina Spriggs, David R. Rueda, Bo R. Galectins and Ovarian Cancer |
title | Galectins and Ovarian Cancer |
title_full | Galectins and Ovarian Cancer |
title_fullStr | Galectins and Ovarian Cancer |
title_full_unstemmed | Galectins and Ovarian Cancer |
title_short | Galectins and Ovarian Cancer |
title_sort | galectins and ovarian cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352943/ https://www.ncbi.nlm.nih.gov/pubmed/32486344 http://dx.doi.org/10.3390/cancers12061421 |
work_keys_str_mv | AT shimadachisa galectinsandovariancancer AT xurui galectinsandovariancancer AT alalemlinah galectinsandovariancancer AT stasenkomarina galectinsandovariancancer AT spriggsdavidr galectinsandovariancancer AT ruedabor galectinsandovariancancer |